Berger Montague Urges ADMA Biologics Investors to Take Action Before August 10, 2026

Important Notice for ADMA Biologics Investors

In a significant development for investors involved with ADMA Biologics, Inc. (NASDAQ: ADMA), notable law firm Berger Montague has announced a class action lawsuit aimed at revealing potential securities fraud. This announcement comes with a crucial deadline for investors, urging action by August 10, 2026.

Founded in Philadelphia, Berger Montague has made a name for itself as a leading firm specializing in complex civil litigation and class actions across the United States. The lawsuit focuses on investors who acquired shares of ADMA during a specified Class Period, which spans from August 9, 2024, to March 25, 2026.

Background of ADMA Biologics

ADMA Biologics is a biopharmaceutical company headquartered in Ramsey, New Jersey. The company is primarily dedicated to developing specialty biologics aimed at treating immune deficiencies and infectious diseases. One of its flagship products, ASCENIV, is designed for treating Primary Humoral Immunodeficiency, marking ADMA as a notable player in the biopharmaceutical space.

However, a recent report by financial analyst Culper Research has cast a shadow over ADMA's operations. Released on March 24, 2026, the report alleges serious discrepancies in the company’s reported revenue growth, indicating that ADMA potentially engaged in deceptive practices such as 'channel stuffing.' According to the findings, the company allegedly encouraged distributors to stock excessive amounts of ASCENIV by providing them with rebates and extended payment terms, thus artificially inflating revenue figures.

Following the publication of this report, ADMA's stock plummeted sharply. Shares saw a decline of 16%, dropping by $2.26 to close at $11.33 per share. This decline continued, with a further drop of 15% the next day, culminating at $9.63 per share.

Call to Action for Investors

ADMA investors are explicitly encouraged to evaluate their position concerning this class action lawsuit. To be considered for a lead plaintiff representative role, they need to make inquiries to Berger Montague by the stated deadline. Interested investors can reach out directly to Andrew Abramowitz or Caitlin Adorni from the firm for further information regarding their rights and options at this pivotal moment.

This lawsuit not only represents potential financial reparation for affected investors but also highlights the critical importance of transparency and accountability in the biopharmaceutical industry.

About Berger Montague

With over 55 years in practice, Berger Montague has a history of significant recoveries for its clients, amounting to more than $50 billion to date. The firm boasts a diverse portfolio, engaging in various legal practices, including antitrust, consumer protection, and securities law among others. The team's expertise ensures that they are well-equipped to handle complex litigation on behalf of investors.

As the August 10 deadline approaches, ADMA investors should act swiftly to safeguard their interests and understand the ramifications of the ongoing legal proceedings. Intrigued parties are invited to contact the law firm to discuss their potential involvement and rights concerning this class action lawsuit.